Anti-infective therapy of the eye - Part 3: Mycotic infections;Antiinfektive medikamentöse therapie am auge - Teil 3: Mykotische infektionen

Klinische Monatsblatter fur Augenheilkunde

Volumn 222, Issue 8, 2005, Pages 605-611

  Behrens Baumann, W ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Additive steroids; Antimycotics; Keratomycosis; Mycosis; Mycotic endophthalmitis; Systemic topical administration

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CASPOFUNGIN; CYCLOSPORIN; ECHINOCANDIN; EYE DROPS; FLUCONAZOLE; FLUCYTOSINE; KETOCONAZOLE; MICONAZOLE; NATAMYCIN; NYSTATIN; OMEPRAZOLE; PREDNISOLONE; STEROID; TACROLIMUS; VORICONAZOLE; WARFARIN;

CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; DRUG INDICATION; ENDOPHTHALMITIS; EYE INFECTION; HUMAN; KERATOMYCOSIS; NEPHROTOXICITY; NONHUMAN; REVIEW; STEROID THERAPY; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 24744444139     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-858452     Document Type: Review

References (97)

1. Adler-Moore JP, Proffitt RT. Entwicklung, Charakterisierung, Wirksamkeit und Wirkungsmodus von Ambisome, einer unilamellaren Liposom-Formulierung von Amphotericin B. J Liposom Res 1993; 3: 429-450
2. Akler ME, Vellend H, McNeely DM et al. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis 1995; 20: 657-664
3. Aliyeva SE, Ullmann AJ, Kottler UB et al. Histological examination of an eye with endogenous Aspergillus endophthalmitis treated with oral voriconazole: a case report. Graefe's Arch Clin Exp Ophtahlmol 2004; 242: 887-891
4. Ally R, Schürmann D, Kreisel W et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-1454
5. Aust R, Kruse FE, Wildfeuer A et al. Fluconazolspiegel im Kammerwasser nach oraler Wirkstoffgabe beim Menschen. Ophthalmologe 1995; 92: 829-832
6. Behrens-Baumann W, Küster M. Der Einfluss von Kortikosteroiden bei der antimykotischen Therapie der Candida-Keratitis. Klin Monatsbl Augenheilkd 1987; 191: 222-225
7. Behrens-Baumann W, Uter W, Ansorg R. Experimentelle Untersuchungen zur lokalen Therapie der Candida-Keratomykose mit Amphotericin B. Klin Monatsbl Augenheilkd 1987; 191: 125-128
8. Behrens-Baumann W, Klinge B. Natamycin (Pimaricin) in der Behandlung der experimentellen Keratomykose. Fortschr Ophthalmol 1990; 87: 237-240
9. Behrens-Baumann W, Klinge B, Rüchel R. Topical fluconazole for experimental Candida keratitis in rabbits. Br J Ophthalmol 1990; 74: 40-42
10. Behrens-Baumann W. Pilzerkrankungen des Auges. Ferdinand Enke Verlag. Stuttgart, 1991 (mit einem Beitrag von R. Rüchel)
11. Behrens-Baumann W, Rüchel R, Zimmermann O et al. Candida tropicalis endophthalmitis following penetrating keratoplasty. Br J Ophthalmol 1991; 75: 565
12. Behrens-Baumann W. Ist die fixe Kombination Kortikosteroid/Antibiotikum am Auge indiziert? Z prakt Augenheilkd 1995; 16: 361-366
13. Behrens-Baumann W. Mycosis of the Eye and Its Adnexa. Developments in Ophthalmology. Basel: S. Karger AG, 1999, 32 (with a contribution by R. Rüchel)
14. Behrens-Baumann W. Antiinfektive medikamentöse Therapie in der Augenheilkunde - Teil 1: Bakterielle Infektionen. Klin Monatsbl Augenheilkd 2004; 221: 539-545
15. Bell RW, Ritchey JP. Subconjunctival nodules after amphotericin B injection. Medical therapy for Aspergillus corneal ulcer. Arch Ophthalmol 1973; 90: 402-404
16. Benson H. Permeability of the cornea to topically applied drugs. Arch Ophthalmol 1974; 91: 313-327
17. Böhme A, Hoelzer D. Liposomal amphotericin B as early empiric anti-mycotic therapy of pneumonia in granulocytopenic patients. Mycoses 1996; 39: 419-426
18. Borne M. Ocular fluconazole treatment of Candida parapsilosis end-ophthalmitis after failed intravitreal amphotericin B. Arch Ophthalmol 1993; 111: 1326-1327
19. Bourcier T, Touzeau O, Thomas F et al. Candida parapsilosis keratitis. Cornea 2003; 22: 51-55
20. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12 (Suppl 1): 318-326
21. Branch RA. Prevention of amphotericin B induced renal impairment. Arch Intern Med 1988; 148: 2389-2394
22. Breit SM, Hariprasad SM, Mieler et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005; 139: 135-140
23. Chapman F, Orr K, Armitage W et al. Candida glabrata endophthalmitis following penetrating keratoplasty. Br J Ophthalmol 1998; 82: 712-713
24. Chick EW, Conant NF. Mycotic ulcerative keratitis. A review of 148 cases from the literature. Invest Ophthalmol 1962; 1: 419
25. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Inf Dis 2002; 34: 563-571
26. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-1151
27. Diaz-Valle D, del Castello JMB, Amor E et al. Severe keratomycosis secondary to Scedosporium apiospermum. Cornea 2002; 21: 516-518
28. Doft BH, Weiskopf J, Nilsson-Ehle I et al. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology 1985; 92: 1601-1605
29. Edwards JE, Foos RY, Montgomerie JZ et al. Ocular manifestations of candida septicemia. Review of seventy six cases of hematogenous candida endophthalmitis. Medicine 1974; 53: 47-75
30. Edwards JJ. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25: 43-59
31. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against oppertunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39: 954-958
32. Figueroa MS, Fortun J, Clement A et al. Endogenous endophthalmitis caused by scedosporium apiospermum treated with voriconazole. Retina 2004; 24: 319
33. Fisher JF, Taylor AT, Clark J et al. Penetration of amphotericin B into the human eye. J Infect Dis 1983; 147: 164
34. Fisher MA, Talbot GH, Maislin G et al. Risk factors for amphotericin-B associated nephrotoxicity. Am J Med 1989; 87: 547-552
35. François J, Rijsselaere M. Corticosteroids and ocular mycoses. Experimental study. Ann Ophthalmol 1974; 6: 207-217
36. François J, Rijsselaere M. Keratomycoses. Ophthalmologica 1979; 179: 32-41
37. Gallis HA, Drew RH, Pickard WW. Amphotericin B. 30 years of clinical experience. Vev Infect Dis 1990; 12: 308-329
38. Gao H, Pennesi ME, Shah K et al. Intravitreal voriconazole. Arch Ophthalmol 2004; 122: 1687-1692
39. Garbino J, Ondrusova A, Baligvo E et al. Successful treatment of paecilomyces lilacinus endophthalmitis with voriconazole. Scand J Infect Dis 2002; 34: 701-703
40. Graf K. Über den Einfluss von Cortison auf das Entstehen von Keratomykosen am Kaninchenauge durch saprophytäre Pilze des menschlichen Bindehautsackes. Klin Monatsbl Augenheilkd 1963; 143: 356-361
41. Grant SM, Clissold SP. Fluconazole. Drugs 1990; 39: 877-916
42. Haggerty TE, Zimmerman LE. Mycotic keratitis. South Med J 1958; 51: 153-159
43. Hariprasad SM, Mieler WF, Holz ER et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004; 122: 42-47
44. Hasany SM, Basu PK, Kazdan JJ. Production of corneal ulcer by opportunistic and saprophytic fungi. 1. The effect of pre-treatment of fungi with steroid. Canad J Ophthalmol 1973; 8: 119-131
45. Heidemann HT, Brune KH. Verhinderung der Amphotericin-B- Nephrotoxizität durch parenteral verabreichtes Flucytosin. Therapiewoche 1987; 37: 4158-4166
46. Heinemann V, Kahny B, Debus A et al. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations. Bone Marrow Transplant 1994; Suppl 5: S8-S9
47. Hoffman HL, Rathbun RC. Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 2002; 11: 409-429
48. Hoffmann DH, Schmitz R. Untersuchungen zum Einfluss des Cortisons auf die experimentelle Candidamykose der Kaninchenhornhaut. Graefes Arch Ophthalmol 1963; 166: 260-276
49. Hoffmann DH, Schmitz R. Die experimentelle Keratomykose als Beitrag zur Frage des Cortisonschadens am Auge. Ein vorläufiger Bericht. Mycosen 1963; 6: 12-20
50. Johns K, O'Day DM. Pharmacologic management of keratomycoses. Surv Ophthalmol 1988; 33: 178-188
51. Kain H. Prinzipien bei der Behandlung der Endophthalmitis. Klin Monatsbl Augenheilkd 1997; 210: 274-288
52. Kaufman HE, Wood RM. Mycotic keratitis. Am J Ophthalmol 1965; 59: 993-1000
53. Kim JE, Perkins SL, Harris GJ. Voriconazole treatment of fungal scleritis and epibulbar abscess resulting from scleral buckle infection. Arch Ophthalmol 2003; 121: 735-737
54. Kirkpatrick WR, Perea S, Coco BJ et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564-2568
55. Kirsh R, Goldstein R, Tarloff J et al. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis 1988; 158: 1065-1070
56. Lazarus HM, Blumer JL, Yanovich S et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002; 42: 395-402
57. Louria DB, Fallon N, Browne HG. The influence of cortisone on experimental fungus infections in mice. J Clin Invest 1960; 39: 1435-1499
58. Maddux MS, Barriere SL. A review of complications of amphotericin B therapy. Recommendations for prevention and management. Drug Intell Clin Pharm 1980; 14: 177-181
59. Marangon FB, Miller D, Giaconi JA et al. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol 2004; 137: 820-825
60. Maurice DM. Structures and fluids involved in the penetration of topically applied drugs. Int Ophthalmol Clin 1980; 20: 7-20
61. Meunier F. Candidiasis. Eur J Clin Microbiol Infect Dis 1989; 8: 438-447
62. Mistlberger A, Graf B. Endogene Candida-Endophthalmitis. Eine neue Therapie. Klin Monatsbl Augenheilkd 1991; 199: 446-449
63. Muallem MS, Alfonso EC, Romano AC et al. Bilateral Candida parapsilosis interface keratitis after laser in situ keratomileusis. J Cataract Refract Surg 2003; 29: 2022-2025
64. Newmark E, Ellison AC, Kaufman HE. Pimaricin therapy of cephalosporium and fusarium keratitis. Am J Ophthalmol 1970; 69: 458-466
65. Newmark E, Ellison AC, Kaufman HE. Combined pimaricin and dexamethasone therapy of keratomycosis. Am J Ophthalmol 1971; 71: 718-722
66. O'Day DM, Moore TE, Aronson SB. Deep fungal corneal abscess. Combined corticosteroid therapy. Arch Ophthalmol 1971; 86: 414-419
67. O'Day DM, Ray WA, Head WS et al. Influence of corticosteroid on experimentally induced keratomycosis. Arch Ophthalmol 1991; 109: 1601-1603
68. Parke DW, Jones DB, Gentry LO. Endogenous endophthalmitis among patients with candidemia. Ophthalmology 1982; 89: 789-796
69. Pelletier R, Loranger L, Marcotte H et al. Voriconazole and fluconazole susceptibility of Candida isolates. J Med Microbiol 2002; 51: 479-483
70. Peng Q, Holzer MP, Kaufer PH et al. Interface fungal infection after laser in situ keratomileusis presenting as diffuse lamellar keratitis. A clinicopathological report. J Cataract Refract Surg 2002; 28: 1400-1408
71. Perraut Jr LE, Perraut LE, Bleiman B et al. Successful treatment of Candida albicans endophthalmitis with intravitreal amphotericin B. Arch Ophthalmol 1981; 99: 1565-1567
72. Perry HD, Doshi SJ, Donnenfeld ED et al. Topical cyclosporin A in the management of therapeutic keratoplasty for mycotic keratitis. Cornea 2002; 21: 161-163
73. Pfaller MA, Messer SA, Hollis RJ et al. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002; 46: 1723-1727
74. Pflugfelder SC, Flynn HW, Zwickey TA et al. Exogenous fungal endophthalmitis. Ophthalmology 1988; 95: 19-30
75. Polack FM, Kaufman HE, Newmark E. Keratomycosis. Arch Ophthalmol 1971; 85: 410-416
76. Polizzi A, Siniscalchi C, Mastromarino A et al. Effect of voriconazole on a corneal abscess caused by fusarium. Acta Ophthalmol Scand 2004; 82: 762-764
77. Potoski BA, Brown J. The safety of voriconazole (correspondence). Clin Infect Dis 2002; 35: 1273-1275
78. Prats CH, Tello FL, San José AB et al. Voriconazole in fungal keratitis caused by scedosporium apiospermum. Ann Pharmacother 2004; 38: 414-417
79. Purkins L, Wood N, Ghahramani P et al. Pharmacokinetics and safety of voriconazole following intravenous to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-2553
80. Reis A, Sundmacher R, Tintelnot K et al. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol 2000; 84: 932
81. Roberts SS. Nystatin in monilia keratoconjunctivitis. Am J Ophthalmol 1957; 44: 108-109
82. Rosa RH, Miller D, Alfonso EC. The changing spectrum of fungal keratitis in South Florida. Ophthalmology 1994; 101: 1005-1013
83. Rowsey JJ, Acers TE, Smith DL et al. Fusarium oxysporum endophthalmitis. Arch Ophtahlmol 1979; 97: 103-105
84. Schreiber W, Olbrisch A, Vorwerk CK et al. Combined topical fluconazole and corticosteroid treatment for experimental Candida albicans keratomycosis. Invest Ophthalmol Vis Sci 2003; 44: 2634-2643
85. Schulman JA, Peyman GA. Intravitreal corticosteroids as an adjunct in the treatment of bacterial and fungal endophthalmitis. Retina 1992; 12: 336-340
86. Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol 2004; 15: 321-327
87. Stern GA, Fetkenhour CL, O'Grady RB. Intravitreal amphotericin B treatment of Candida endophthalmitis. Arch Ophthalmol 1977; 95: 89-93
88. Stransky TJ. Postoperative endophthalmitis secondary to Candida parapsilosis: a case treated by vitrectomy and intravitreous therapy. Retina 1981; 1: 179-185
89. Thomas PA. Fungal infections of the cornea. Eye 2003; 17: 852-862
90. Troke P Multicentre European Study Group. Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. Eur J Clin Microbiol Infect Dis 1997; 16: 287-295
91. Urbak SF, Degn T. Fluconazole in the treatment of Candida albicans endophthalmitis. Acta Ophthalmol 1992; 70: 528-529
92. Varma D, Thaker HR, Moss PJ et al. Use of voriconazole in candida retinitis. Eye 2004: 1-2
93. Walsh TJ, Lutsar I, Driscoll T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-248
94. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402
95. Windholz M, Budavari S, Blumetti RF et al. The Merck Index. Merck 1983
96. Zadok D, Karpuch J. Treatment of multiple corneal abscesses with fluconazole. Clin Infect Dis 1994; 18: 482-484
97. Zhou L, Glickman RD, Chen N et al. Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry. J Chromatogr B 2002; 776: 213-220